Skip to main content
PLOS One logoLink to PLOS One
. 2022 Nov 14;17(11):e0277016. doi: 10.1371/journal.pone.0277016

Influencing factor of COVID-19 vaccination trust and hesitancy in Wonju city, South Korea

Hocheol Lee 1, Eun Bi Noh 2, Ji Eon Kim 1, Juyeon Oh 3, Eun Woo Nam 1,2,4,*
Editor: Harapan Harapan5
PMCID: PMC9662712  PMID: 36374920

Abstract

Social capital (SC) has been documented to effectively reduce the spread of diseases, including COVID-19; however, research pertaining to SC and COVID-19 vaccination in Korea is lacking. This cross-sectional study conducted in the city of Wonju, Gangwon Province, Korea (n = 1,096) examined the differences in COVID-19 vaccine trust and hesitancy considering individual characteristics and investigated the effects of SC on COVID-19 vaccine trust and hesitancy. SC was measured based on 14 items pertaining to social trust, network, and norms. Responses regarding COVID-19 screening history, vaccine trust, and vaccine hesitancy were also assessed. SC scores did not differ between sexes, but differed significantly according to age and household income; thus, adults aged 70–79 years had the highest SC scores, and mean SC score increased significantly with income. COVID-19 vaccine trust differed significantly according to age, average household income, social organization involvement, and SC score. COVID-19 vaccine hesitancy differed significantly with age, SC score, and COVID-19 screening history. In univariate logistic regression, age, average household income, social organization involvement, and SC score were significant predictors of vaccine trust; in multivariable analysis, however, the identified predictors were age and SC. In particular, people with an SC score ≥50 were 2.660 times more likely to trust COVID-19 vaccines than those with lower scores. In multivariable analysis, age and SC were significant predictors of vaccine hesitancy. In particular, people with an SC score ≥50 were 1.400 times more likely not to be hesitant about receiving COVID-19 vaccines than people with lower scores. These results indicate that prioritizing policies to increase SC and trust in the government could boost the COVID-19 vaccination rate.

Introduction

Since the first case of coronavirus disease 2019 (COVID-19) was reported in Korea on January 19, 2020, there have been a total of 24,740,635 cases and 28,364 deaths as of September 29, 2022 [1]. Following the World Health Organization (WHO) vaccination guidelines, Korea began COVID-19 vaccine rollout in February 2021—starting from healthcare workers and moving on to older adults, epidemiology personnel, high-risk groups, and the general population—with a plan to achieve herd immunity by completely vaccinating 70% of the population by November 2021 [2]. The goal has been met, with an 86.3% vaccination rate as of September 2022.

In the Core Capacity Workbook for International Health Regulations, the World Health Organization (WHO) the following eight core capacities for the control and prevention of the spread of infectious diseases: a) National legislation, policy, and financing; b) Coordination and communications; c) Surveillance; d) Response; e) Preparedness; f) Risk communication; g) Human resources; and h) Laboratory [3]. Furthermore, it emphasized that governments should be equipped with adequate vaccine transport infrastructure, healthcare facilities, risk communication and monitoring systems, finances, and social capital (SC) to recommend COVID-19 vaccination [4].

SC was defined as “shared values in relation to connections and networks among individuals.” It particularly encompasses social activities, trust, norms, and attachment [5, 6] and has been consistently documented as strongly associated with individuals’ physical and mental health [7]. SC is also effective in alleviating the direct and indirect health threats posed by the COVID-19 pandemic. Previous studies in Korea and the United States have reported that regions with higher SC responded more proactively to the spread of COVID-19 and showed reduced spread of the disease [810],. In particular, groups with high trust in the government, a factor of SC, strictly adhered to COVID-19 guidelines for the good of the social network (community) and limited their daily movements in compliance with the government mandate [10].

The Korean government has initiated its COVID-19 vaccine rollout to achieve herd immunity by the second half of 2021. To this end, the government has striven to boost public trust in COVID-19 vaccines and encourage vaccination. Furthermore, research has consistently reported that vaccination is strongly correlated with income level [11]. While some studies have reported that SC positively impacts the decision to get vaccinated against COVID-19, research or evidence pertaining to SC and COVID-19 vaccination in Korea is lacking.

This study aimed to identify the influencing factors of COVID-19 vaccine trust and hesitancy, with two specific objectives: 1) to examine the differences in COVID-19 vaccine trust and hesitancy according to various participant characteristics and 2) to investigate the effects of SC on COVID-19 vaccine trust and hesitancy.

Methods

Study design

This cross-sectional study was conducted in the city of Wonju, Gangwon Province, Republic of Korea. The city of Wonju is divided into 14 dong (urban areas) and 9 myeon (rural areas). In 2020, its population was 357,710, of whom 290,157 were adults. In 2021, the city implemented a five-year health plan, which includes measures for COVID-19 vaccination. Hence, this study aims to investigate the association of COVID-19 vaccine trust and hesitancy with SC to present useful data for devising COVID-19 policies. The study population comprised Korean adult (≥ 20 years) residents of Wonju.

Study instrument

The study instrument was developed with a focus on SC, COVID-19 responses, and general characteristics. First, SC was measured based on 14 items pertaining to social trust (4 items), social network (5 items), and social norms (5 items), with each item rated on a 5-point Likert-type scale. Second, COVID-19-related responses were assessed using items developed in the context of the study region and based on the annual Community Health Survey conducted by Statistics Korea. The questions asked were regarding COVID-19 screening history, COVID-19 vaccine trust, and COVID-19 vaccine hesitancy. The general characteristics assessed were sex, age, average household income, and area of residence. Ages were divided into 20s, 30s, 40s, 50s, and 60s. House income was classified as <1 million, 1–1.99 million, 2–2.99 million, 3–3.99 million, 4–4.99 million, and >5 million. This was based on the classification table of the Community Health Survey in Korea. Social organization involvement was divided into involved (1) and not involved (0) and included involvement in community or organizations, such as volunteering, young adult groups, older adult groups, married women groups, parent associations, sports clubs, self-governing bodies, and religious organizations.

Data collection

Adult residents of Wonju aged 20 years or older were enrolled in this study. The study sample was extracted via probability proportional to size sampling to ensure that it was representative of the population. In Step 1, the sample size was allocated proportionately to age and population for each of the 23 urban and rural areas of WonjuIn Step 2, households were randomly selected from the list of households of a village within each sample stratified by age and sex, and a questionnaire survey was administered to these households. Using Raosoft, the minimum sample size required for a confidence level of 95% and significance of 5% was calculated at 1,197.

For the questionnaire survey, 18 enumerators were hired and trained from April 26 to May 3, 2022. A pilot survey was conducted in four regions on May 5, and the main survey was conducted from May 7 to May 17. The pilot survey was conducted on 100 participants in two urban and two rural regions, and reliability (Cronbach’s alpha) was found to be .86. Further, the content and construct validities of the questionnaire were determined based on the results of the pilot survey.

A total of 1,248 participants completed the survey. After excluding those with careless responses (e.g. censored respondents) and those who withdrew from the survey, a total of 1,096 participants were included. In detail, 152 participants were identified as careless responders, including 113 who withdrew from the study (74.3%), 27 who mutilated the questionnaire (17.7%), and 12 who did not consent to participate in the final step of the study (7.8%). We thus analyzed 87.82% (1,096/1,248) of the collected data. We obtained informed consent in written form from all the respondents. They were also informed of their right to refuse to answer any question.

Statistical analysis

We used the following statistical techniques to analyze the effects of SC on COVID-19 vaccine trust and hesitancy. First, SC according to each characteristic was visualized using box plots. Further, the differences in SC according to participants’ characteristics were analyzed using t-tests. Second, the differences in COVID-19 vaccine trust and hesitancy according to general characteristics, social organization involvement, SC score, and COVID-19 infection history were analyzed using Pearson’s chi-square tests. Third, predictors of COVID-19 vaccine trust and hesitancy were identified using binary logistic regression. All regression coefficients, odds ratios, t-values, and p-values were examined to determine the predictability of each factor of COVID-19 vaccine trust and hesitancy.

All statistical analyses were conducted using STATA 15(Stata Corporation, College Station, TX, USA), and the data were visualized using the R-4.11 (R Foundation for Statistical Computing, Vienna, Austria).

Ethical considerations

All components of this survey were approved by the institutional review board (IRB) of Yonsei University (IRB document number: 1041849-202104-SB-063-02).

Results

Participant characteristics

There were more urban (72.4%) than rural dwellers (27.6%) and more men (53.5%) than women (46.5%) among the study participants. The most common age group was over 60 years (22.0%). A total of 31.0% of the participants were involved in a social organization, and 60.4% had an SC score of <50. A total of 23.3% of the participants had undergone COVID-19 screening, 30.2% trusted COVID-19 vaccines, and 62.2% were willing to be vaccinated against COVID-19. The most common household income was ≥ 5 million KRW (22.4%) (Table 1).

Table 1. Characteristics of respondents (n = 1,096).

N %
Area of residence
 Urban 793 72.4
 Rural 303 27.6
Sex
 Male 586 53.5
 Female 510 46.5
Age
 20–29 years 224 20.4
 30–39 years 212 19.3
 40–49 years 206 18.8
 50–59 years 213 19.4
 ≥ 60years 241 22.0
Average household income
 ≤ 1 million KRW 113 103
 1.00–1.99 million KRW 136 12.4
 2.00–2.99 million KRW 202 18.4
 3.00–3.99 million KRW 233 21.3
 4.00–4.99 million KRW 166 15.1
 ≥ 5 million KRW 246 22.4
Social organization involvement
 Yes 340 31.0
 No 756 69.0
Social capital score
 <50 662 60.4
 ≥50 434 39.6
COVID-19 screening
 Yes 255 23.3
 No 841 76.7
COVID-19 vaccine trust
 Yes 331 30.2
 No 765 69.8
COVID-19 vaccine hesitancy
 Not hesitant 682 62.2
 Hesitant 414 37.8

KRW: Korean won

The visualization of SC scores based on participant characteristics using box plots showed that SC scores did not differ between sexes, but did differ significantly according to age, with adults aged 70–79 years having the highest SC scores (p<0.001). SC score also differed according to household income, with the mean SC score increasing significantly with increasing income (p<0.001). While the mean SC score was lower in the socially involved group, there were many outliers. Moreover, SC scores differed according to COVID-19 vaccine trust, with the group that did not trust COVID-19 vaccines having higher SC scores (p<0.001). Individuals with as opposed to without vaccine hesitancy showed significantly higher SC (p < .001). Urban dwellers displayed higher SC than rural dwellers but not to a significant extent (p = .945) (Fig 1).

Fig 1. Social capital by participant characteristics.

Fig 1

COVID-19 trust and hesitancy by participant characteristics

Next, the differences in COVID-19 vaccine trust and hesitancy according to participant characteristics were analyzed using Pearson’s chi-squared tests. COVID-19 vaccine trust differed significantly according to age (p<0.001), average household income (p = 0.040), social organization involvement (p = 0.001), and SC score (p<0.001). COVID-19 vaccine hesitancy differed significantly according to age (p < .001), SC score (p = 0.003), and COVID-19 screening history (p = 0.039) (Table 2).

Table 2. Differences in COVID-19 vaccine trust and hesitancy.

COVID-19 vaccine trust χ2(p) COVID-19 vaccine hesitancy χ2(p)
Yes No Yes No
Area of residence
 Urban 299 (28.9%) 564 (71.1%) 2.382 (0.123) 499 (63.1%) 292 (36.9%) 0.675 (0.411)
 Rural 102 (33.7%) 201 (63.3%) 183 (60.4%) 120 (39.6%)
Sex
 Male 189 (32.3%) 397 (67.7%) 2.515 (0.113) 363 (61.9%) 223 (38.1%) 0.084 (0.772)
 Female 142 (27.8%) 368 (72.2%) 319 (62.8%) 189 (37.2%)
Age
 20–29 years 39 (17.4%) 185 (82.6%) 58.881. (<0.001) 117 (52.5%) 106 (47.5%) 35.972 (<0.001)
 30–39 years 46 (21.7%) 166 (78.3%) 111 (52.4%) 101 (47.6%)
 40–49 years 59 (28.6%) 147 (71.4%) 144 (69.9%) 62 (30.1%)
 50–59 years 74 (34.7%) 139 (65.3%) 142 (66.7%) 71 (33.3%)
 ≥60 years 113 (46.9%) 128 (53.1%) 168 (70.0%) 72 (30.0%)
Average household income
 ≤ 1 million KRW 49 (43.4%) 64 (56.6%) 11.666 (0.040) 69 (61.1%) 44 (38.9%) 3.876 (0.567)
 1.00–1.99 million KRW 40 (29.4%) 96 (70.6%) 78 (57.4%) 58 (42.6%)
 2.00–2.99 million KRW 52 (25.7%) 150 (74.3%) 125 (61.9%) 77 (38.1%)
 3.00–3.99 million KRW 66 (28.3%) 167 (71.7%) 143 (61.4%) 90 (38.6%)
 4.00–4.99 million KRW 49 (29.5%) 117 (70.5%) 112 (67.9%) 53 (32.1%)
 ≥ 5 million KRW 75 (30.5%) 171 (69.5%) 155 (63.3%) 90 (32.1%)
Social organization involvement
 Yes 127 (27.0%) 213 (73.0%) 11.961 (0.001) 221 (61.1%) 119 (38.9%) 1.487 (0.223)
 No 204 (37.4%) 552 (62.6%) 461 (65.0%) 293 (35.0%)
Social capital score
 <50 142 (21.5%) 520 (78.5%) 60.727 (<0.001) 388 (56.9%) 272 (41.2%) 8.941 (0.003)
 ≥50 189 (43.5%) 245 (56.5%) 294 (67.7%) 140 (32.3%)
COVID-19 screening
 Yes 71 (30.9%) 184 (69.1%) 0.876 (0.349) 145 (64.0%) 110 (36.0%) 4.249 (0.039)
 No 260 (27.8%) 581 (72.2%) 537 (56.9%) 302 (43.1%)

KRW: Korean won

Predictors of COVID-19 vaccine trust and hesitancy

Binary logistic regression analysis was performed to identify the predictors of COVID-19 vaccine trust and hesitancy. In the univariate analysis of vaccine trust, age, average household income, social organization involvement, and SC score were identified as significant predictors. In the multivariable analysis, age and SC score were identified as significant predictors. In particular, people with an SC score of ≥50 were 2.660 times more likely to trust COVID-19 vaccines than those with an SC score of <50 (p<0.001).

In multivariable logistic regression analysis of predictors of COVID-19 hesitancy, age and SC were identified as significant predictors. In particular, people with an SC score of ≥50 were 1.400 times more likely not to be hesitant about receiving COVID-19 vaccines than people with an SC score of <50 (p<0.01) (Table 3).

Table 3. Results of logistic regression for predictors of COVID-19 vaccine trust and hesitancy.

Variable COVID-19 vaccine trust COVID-19 vaccine hesitancy
cOR 95% CI aOR 95% CI cOR 95% CI aOR 95% CI
Area of residence
 Urban Ref. Ref. Ref Ref.
 Rural 1.250 0.941–1.659 1.185 0.874–1.606 0.892 0.680–1.171 0.858 0.648–1.135
Sex
 Male Ref. Ref. Ref Ref.
 Female .811 0.625–1.051 .808 0.612–1.066 1.037 0.811–1.325 1.018 0.790–1.312
Age
 20–29 years Ref. Ref. Ref Ref.
 30–39 years 1.314 0.817–2.114 1.369 0.835–2.246 0.982 0.683–1.451 0.976 0.663–1.438
 40–49 years 1.904** 1.203–3.012 2.000** 1.230–3.230 2.104*** 1.415–3.130 2.049** 1.359–3.090
 50–59 years 2.525*** 1.617–3.944 2.386*** 1.488–3.8263.819 1.812** 1.230–2.670 1.706* 1.138–2.558
 ≥60 years 4.188*** 2.729–6.425 3.710**** 2.323–5.923 2.114*** 1.444–3.095 2.225*** 1.469–3.370
Average household income
 ≤1 million KRW Ref. Ref. Ref Ref.
 1.00–1.99 million KRW .544* 0.322–0.919 0.643 0.366–1.128 0.858 0.516–1.426 0.573 0.573–1.636
 2.00–2.99 million KRW .453** 0.278–0.737 0.628 0.370–1.067 1.035 0.645–1.661 1.337 0.812–2.202
 3.00–3.99 million KRW .516** 0.323–0.825 0.15 0.432–1.237 1.013 0.639–1.607 1.217 0.746–1.984
 4.00–4.99 million KRW .547** 0.332–0.902 0.687 0.410–1.149 1.348 0.818–2.221 1.553 0.911–2.647
 ≥5 million KRW .573** 0.361–0.908 0.841 0.410–0.245 1.098 0.694–1.737 1.383 0.845–2.262
Social organization involvement
 Yes Ref. Ref. Ref Ref.
 No 1.613*** 1.229–2.118 1.065 0.790–1.4207 1.180 0.904–1.541 .965 0.724–1.287
COVID-19 screening
 No Ref. Ref. Ref Ref.
 Yes .862 0.632–1.176 1.006 0.723–1.402 0.741* 0.557–0.986 0.803 0.598–1.819
Social capital score
 <50 Ref. Ref. Ref Ref.
 ≥50 2.825*** 2.166–3.684 2.660*** 2.018–3.504 1.472** 1.142–1.898 1.400** 1.077–1.819
Hosmer–Lemeshow .222 .112

*p<0.05,

**p<0.01,

***p<0.001

KRW: Korean won, aOR: adjusted odds ratio

Discussion

This study aimed to analyze the effects of SC on COVID-19 vaccine trust and hesitancy. Our results showed that SC scores did not differ between sexes but differed significantly according to age and increased with increasing household income. COVID-19 vaccine trust differed significantly according to age, average household income, social organization involvement, and SC score. COVID-19 vaccine hesitancy differed significantly according to age, SC score, and COVID-19 screening history. In univariate logistic regression, age, average household income, social organization involvement, and SC score were found to be significant predictors of vaccine trust; in multivariable analysis, the identified predictors were age and SC. In multivariable analysis, age and SC were significant predictors of vaccine hesitancy.

Regarding the demographic characteristics of the participants, 72.4% were urban dwellers, which was similar to the reported percentage of urban dwellers (76.6%) for the city of Wonju [12], an urban-rural complex city. A total of 31.0% of the participants were involved in a social organization, which was higher than the rate (23.0%) reported in a previous study [13]. In our study, 30.2% of the participants stated that they trusted COVID-19 vaccines, which was lower than the global rate of vaccine trust (42.2%) [14]. Regarding COVID-19 vaccine hesitancy, 62.2% of the participants said they were not hesitant about being vaccinated, which was low considering that the average level of willingness to be vaccinated against COVID-19 worldwide is higher than 70.0% [15, 16]. The reasons for this low willingness may include the continuous decline of the Korean government’s approval ratings, limitations of risk communication, and spread of negative views due to the COVID-19 infodemic via the Internet and media [17]. A strong belief in inaccurate information about COVID-19 has been found to be influenced more by social media than the news [18], and considering that social media usage escalated by 87% during the COVID-19 pandemic compared to that in the pre-COVID-19 period, the younger generation—comprising the predominant users of social media—is likely to be vulnerable to the infodemic [19]. In addition to these factors, other personal factors such as education and income levels were found to have a strong influence on COVID-19 vaccine acceptance. By the same token, we speculate that the educational and income gaps that exist between the urban and rural regions of Wonju might have influenced vaccine acceptance [11].

SC has been reported to influence health, well-being, social support, sociability, and social standing; it has a particularly greater impact on older adults [2022]. In our study sample, SC increased with age and increasing social involvement. One of the reasons for higher SC among older individuals is that older people engage in fewer economic activities, and social welfare policies are mostly focused on recommending and encouraging the social involvement of older adults [23].

The first objective of this study was to analyze the differences in COVID-19 vaccine trust and hesitancy according to the various characteristics of the study participants. COVID-19 vaccine trust was found to differ significantly according to age, household income, social involvement, and SC score, while COVID-19 vaccine hesitancy differed significantly according to age, SC score, and COVID-19 screening history. We confirmed that COVID-19 vaccine trust and acceptance increased significantly with advancing age, which is consistent with previous findings [24]. In particular, a recent telephonic survey of 1,200 people in Hong Kong showed that 42.2% of the respondents trusted COVID-19 vaccines and were willing to be vaccinated. By age, the COVID-19 vaccine acceptance rate was below 10% in the age group 16–54 years, but it increased with advancing age to 21.7% among those aged ≥55 years and 53.5% among those aged ≥65 years [24]. On the other hand, a Southeast Asian study reported that older adults are indeed vulnerable to COVID-19, but most of this population is retired and spends most of its time at home. Therefore, the study argued that the older adult population is at a lower risk of exposure to COVID-19 and, consequently, shows lower vaccine acceptance [25].

Increased COVID-19 vaccine trust and acceptance with advancing age is associated with the channels through which individuals acquire information and also the frequency of receiving information. Young individuals are frequently exposed to potentially inaccurate information through social media and are likely to encounter rumors and misinformation. In contrast, older adults generally obtain information about COVID-19 vaccines through public mass media, such as news outlets, and they are thus given relatively more credible information, which has probably contributed to boosting their COVID-19 vaccine trust [18]. Contrariwise, people who are provided with correct information have a detailed understanding of the risks of COVID-19 and, consequently, show high vaccine hesitancy [11]. However, as the WHO continually advocates the safety of COVID-19 vaccines based on literature evidence, the Korean government continues to recommend and promote vaccination through the media.

The second objective of this study was to identify the predictors of COVID-19 vaccine trust and hesitancy. Age and SC score were identified as predictors of COVID-19 vaccine trust and hesitancy. People with higher SC scores showed higher levels of COVID-19 vaccine trust and acceptance. SC comprises four dimensions—civic engagement, trust in the government, social belonging, and social trust—and a high SC score indicates that the individual trusts both the social community and the government and is actively involved in activities as a member of the society [26, 27]. Previous studies have reported that SC is effective in provoking behaviors that reduce COVID-19-related health risk [9], and that regions with greater SC deal with infectious diseases more proactively and thus have fewer cases in the community [7, 8]. SC-oriented public health responses can complement the limitations of top-down policies, and it is important to boost social solidarity and trust to achieve the public health goal of battling COVID-19 [28]. Thus, SC is expected to increase the COVID-19 vaccination rate and positively contribute to the efforts of communities to halt the spread of the disease. In particular, a previous study has reported that civic engagement and trust in the government had positive effects on COVID-19 responses, while trust in and a sense of belonging in affiliated groups had a negative effect on COVID-19 responses [29]. Another study reported that among the various elements of SC, low trust in institutions hindered COVID-19 response measures such as physical distancing [30].

Moreover, societies with high social trust may actually be more vulnerable to fake news about the severity of COVID-19, fake treatments, and criticisms against policies such as physical distancing [31].

This study has a few limitations. First, due to the cross-sectional study design, we could not identify the causative factors in a time-series analysis from 2020, when the index case of COVID-19 occurred in Korea. Second, although the city of Wonju, where this study was conducted, has a population of 300,000, the findings cannot be expected to be nationally representative. Subsequent studies should recruit participants from other and more diverse regions to ensure the generalizability of the findings in Korea.

Conclusion

This study confirmed that SC is a predictor of COVID-19 vaccine trust and hesitancy, and that people with higher SC have greater trust in COVID-19 vaccines and are more willing to be vaccinated. The Korean government chose herd immunity as a key strategy for controlling COVID-19 and has implemented COVID-19 vaccination plans accordingly. Our results suggest that the government should strive to increase SC to boost the COVID-19 vaccination rate, which is crucial in pursuing long-term COVID-19 response measures to combat the prolonged pandemic. In particular, the government should prioritize policies to increase social involvement and trust in the government. To this end, the Korean government will need to transparently provide reliable COVID-19 information through various channels such as the media and the Internet through COVID-19 experts and trusted celebrities to increase its credibility.

Supporting information

S1 File

(PDF)

S2 File

(PDF)

Acknowledgments

We express our gratitude to everyone working to overcome COVID-19 in South Korea and throughout the world. Furthermore, we express our gratitude to the Healthy City team, Wonju City Hall.

Data Availability

Data cannot be shared without permission by Wonju city hall (Healthy City team) publicly, South Korea. Data are available from the Wonju city hall Institutional Data Access (contact via Yeon-seok Jin, jys12076@korea.kr) / Ethics Committee (contact via yuwirb@yonsei.ac.kr/ https://e-irb.yonsei.ac.kr/index.htm?) for researchers who meet the criteria for access to confidential data.

Funding Statement

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1C1C2005464). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.ncov.mohw.go.kr/en/ [Internet]. Sejong: Ministry of Health and Welfare; 2022 [cited 2016 Dec 27]. http://ncov.mohw.go.kr/en/
  • 2.Korea Centers for Disease Control & Prevention. Free vaccination for all citizens of COVID-19 to return to daily life. Cheongju: Korea Centers for Disease Control & Prevention; 2021. [Google Scholar]
  • 3.World Health Organization [Internet]. Geneva: World Health Organization; c2022 [cited 2016 Dec 27]. IHR (2005) Core Capacity Workbook: a series of exercises to assist the validation of core capacity implementation levels. https://www.who.int/publications/i/item/WHO-HSE-GCR-2015.13
  • 4.Felter C. A guide to global COVID-19 vaccine efforts. Council on Foreign Relations [Internet]. 2021 Jun 30 [cited 2016 Dec 27]. https://www.jstor.org/stable/resrep33363
  • 5.Coleman JS. Social capital in the creation of human capital. Am J Sociol. 1988;94:S95–S120. doi: 10.1086/228943 [DOI] [Google Scholar]
  • 6.Putnam RD. Bowling alone: the collapse and revival of American community. New York: Simon and Schuster; 2000. [Google Scholar]
  • 7.Rodgers J, Valuev AV, Hswen Y, Subramanian SV. Social capital and physical health: an updated review of the literature for 2007–2018. Soc Sci Med. 2019;236:112360. doi: 10.1016/j.socscimed.2019.112360 [DOI] [PubMed] [Google Scholar]
  • 8.Borgonovi F, Andrieu E. Bowling together by bowling alone: social capital and COVID-19. Soc Sci Med. 2020;265:113501. doi: 10.1016/j.socscimed.2020.113501 [DOI] [PubMed] [Google Scholar]
  • 9.Makridis CA, Wu C. How social capital helps communities weather the COVID-19 pandemic. PLOS ONE. 2021;16(9):e0258021. doi: 10.1371/journal.pone.0258021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jang SH. Social-ecological factors related to preventive behaviors during the COVID-19 pandemic in South Korea. PLOS ONE. 2022;17(3):e0266264. doi: 10.1371/journal.pone.0266264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sallam M, Anwar S, Yufika A, Fahriani M, Husnah M, Kusuma HI, et al. Willingness-to-pay for COVID-19 vaccine in ten low-middle-income countries in Asia, Africa and South America: a cross-sectional study. Narra J. 2022;2(1). doi: 10.52225/narra.v2i1.74 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wonju Statistical Information [Internet]. Gangwon-do: Wonju Statistical Information; 2020 [cited 2016 Dec 27]. Resident registration demographics. https://stat.wonju.go.kr/board/board.php?b_id=res_stat
  • 13.Yıldızer G, Bilgin E, Korur EN, Novak D, Demirhan G. The association of various social capital indicators and physical activity participation among Turkish adolescents. J Sport Health Sci. 2018;7:27–33. doi: 10.1016/j.jshs.2017.10.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Willis DE, Andersen JA, Bryant-Moore K, Selig JP, Long CR, Felix HC, et al. COVID‐19 vaccine hesitancy: race/ethnicity, trust, and fear. Clin Transl Sci. 2021;14:2200–2207. doi: 10.1111/cts.13077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines. 2021;9:160. doi: 10.3390/vaccines9020160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Trent M, Seale H, Chughtai AA, Salmon D, MacIntyre CR. Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: a comparative survey of five large cities in the United States, United Kingdom, and Australia. Vaccine. 2022;40:2498–2505. doi: 10.1016/j.vaccine.2021.06.048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lee H, Noh EB, Choi SH, Zhao B, Nam EW. Determining public opinion of the COVID-19 pandemic in South Korea and Japan: social network mining on twitter. Healthc Inform Res. 2020;26:335–343. doi: 10.4258/hir.2020.26.4.335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Nielsen RK, Fletcher R, Newman N, Brennen JS, Howard PN. Navigating the ‘infodemic’: how people in six countries access and rate news and information about coronavirus. Oxford: Reuters Institute; 2020. [Google Scholar]
  • 19.Sharma P, Raje M, Savant S, Savant R. When infodemic overtakes Covid-19 in spreading far and wide. Ann Rom Soc Cell Biol. 2021;25(4):4721–4730. [Google Scholar]
  • 20.Cramm JM, Van Dijk HM, Nieboer AP. The importance of neighborhood social cohesion and social capital for the well being of older adults in the community. Gerontologist. 2013;53:142–152. doi: 10.1093/geront/gns052 [DOI] [PubMed] [Google Scholar]
  • 21.Lin N, Erickson BH, editors. Social capital: an international research program. New York: Oxford University Press; 2010. [Google Scholar]
  • 22.Nieminen T, Prättälä R, Martelin T, Härkänen T, Hyyppä MT, Alanen E, et al. Social capital, health behaviours and health: a population-based associational study. BMC Public Health. 2013;13:613. doi: 10.1186/1471-2458-13-613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Gray A. The social capital of older people. Ageing Soc. 2009;29:5–31. doi: 10.1017/S0144686X08007617 [DOI] [Google Scholar]
  • 24.Wong MCS, Wong ELY, Huang J, Cheung AWL, Law K, Chong MKC, et al. Acceptance of the COVID-19 vaccine based on the health belief model: a population-based survey in Hong Kong. Vaccine. 2021;39:1148–1156. doi: 10.1016/j.vaccine.2020.12.083 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Acceptance of a COVID-19 vaccine in Southeast Asia: a cross-sectional study in Indonesia. Front Public Health. 2020;8:381. doi: 10.3389/fpubh.2020.00381 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Pearson AL. The (social distanced) circle of family, friends, and allies: how COVID-19 is re-shaping social capital and new opportunities for research. In: Andrews GJ, Crooks VA, Pearce JR, Messina JP, editors. COVID-19 and similar futures. Global perspectives on health geography. Cham: Springer; 2021. pp. 139–145. [Google Scholar]
  • 27.Jiang N, Lou VWQ, Lu N. Does social capital influence preferences for aging in place? Evidence from urban China. Aging Ment Health. 2018;22:405–411. doi: 10.1080/13607863.2016.1249455 [DOI] [PubMed] [Google Scholar]
  • 28.Wong ASY, Kohler JC. Social capital and public health: responding to the COVID-19 pandemic. Global Health. 2020;16:88. doi: 10.1186/s12992-020-00615-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Villalonga-Olives E, Kawachi I. The dark side of social capital: a systematic review of the negative health effects of social capital. Soc Sci Med. 2017;194:105–127. doi: 10.1016/j.socscimed.2017.10.020 [DOI] [PubMed] [Google Scholar]
  • 30.Dezecache G, Frith CD, Deroy O. Pandemics and the great evolutionary mismatch. Curr Biol. 2020;30:R417–R419. doi: 10.1016/j.cub.2020.04.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zmerli S. Social capital and norms of citizenship: an ambiguous relationship? Am Behav Sci. 2010;53:657–676. doi: 10.1177/0002764209350829 [DOI] [Google Scholar]

Decision Letter 0

Sergio A Useche

20 Jun 2022

PONE-D-21-29174Association between social capital and COVID-19 vaccine trust and hesitancyPLOS ONE

Dear Dr. Nam,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Apologies for the delay, and thanks for your patience. After experiencing a great reluctance from many possible candidates (a sensitive topic)n, this paper has been reviewed by an acknowledged expert in this field. Overall, our referee highlights the interest raised by the manuscript, but also emphasizes on several technical & analytical shortcomings that must be amended by the authors before reconsidering this manuscript for publication. Therefore, the revisions required are basically major. Please find the comments below, at the end of this email.

Please submit your revised manuscript by Aug 04 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Sergio A. Useche, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

4. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

5. Thank you for stating the following financial disclosure: "This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1C1C2005464)."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

6. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I read the manuscript entited "Association between social capital and COVID-19 vaccine trust and hesitancy". The concept is interesting but already it is old idea. I see many article in online about the COVID-19 vaccine hesitency. However, most of them are missing in present manuscript. Therefore, authors need to improve introduction and discussion based on present published articles. See some specific comments bellow:

- consent from individual was missing. If you have that, add in the data colection section

-Table 1: Age categories should be minimized, so many catagories is meaningless. So I suggested to have only 3/4 categories of age.

-How you divided the household incomes? You need to add references in the method section, how you divided the income division? Accordingly, re-arrange the Table 1 based on income categories!

-Rearrange Table 2 and 3 based on re-arranged categories of age and household incomes.

-What is your key findings from your study? Need to explain key messages in the conclusion part. Based on the key message, what is your recommendations.

-In Figure 1, you need to adjust age, and household incomes.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Nov 14;17(11):e0277016. doi: 10.1371/journal.pone.0277016.r002

Author response to Decision Letter 0


8 Jul 2022

We very appreciate you once again for receiving that comment by reviewers.

We tried to revise/change by following the comments of reviewers.

As result, we agreed this manuscript improved its quality due to comments.

We hope to hear a positive decision from Reviewers, Editorial Board and Editor.

Thank you again.

Eun Woo Nam

Hocheol Lee

Attachment

Submitted filename: 3-2. [#Reviewer Comments] response to reviewer.docx

Decision Letter 1

Harapan Harapan

1 Sep 2022

PONE-D-21-29174R1Association between social capital and COVID-19 vaccine trust and hesitancyPLOS ONE

Dear Dr. Nam,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 16 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Harapan Harapan, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Additional Editor Comments:

Please revised your manuscript based on the previous suggestion of the reviewers. Fail to do so will result rejection. I will ask for next round review to the reviewers

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Nov 14;17(11):e0277016. doi: 10.1371/journal.pone.0277016.r004

Author response to Decision Letter 1


4 Sep 2022

Dear Reviewers,

First, we are very appreciated for your helpful review. I discussed with all authors for your comments. And we revised/corrected the context as all manuscript.

We attached the two manuscripts, 1) clean manuscript, 2) tracked manuscript. In the ’ 2) track manuscript’ file, our responses/revisions are highlighted using tracked system on word.

Thank you for review in advance.

Prof. Eun Woo Nam.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Harapan Harapan

19 Sep 2022

PONE-D-21-29174R2Association between social capital and COVID-19 vaccine trust and hesitancyPLOS ONE

Dear Dr. Nam,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 03 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Harapan Harapan, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments:

One of the reviewers attached the file. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: No

Reviewer #3: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: No

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thank you for the opportunity of reviewing the manuscript whose objective of is to analyze the differences in COVID-19 vaccine trust and hesitancy according to the various participants’ characteristics, including the social capital. Please find below my comments:

Title

1. I’m pretty sure the study does not only cover the association between social capital and COVID-19 vaccine. Other factors are also studied. Please modify the title to be more representative of the content.

Introduction

1. Line 51. “eight core capacities” please elaborate.

2. Line 59. “SC has been fund to effectively” please check the accuracy

3. Line 60—61. “Previous studies have reported that regions with higher SC..” Where were the studies conducted? The elaboration is important because the submitted study has a novelty of its population being Koreans.

4. Is COVID-19 vaccination a mandatory in Korea? How is the progress so far?

5. To strengthen the background authors may incorporate the following studies revealing about the COVID-19 acceptance. And please focus on the detailed factors (such as income, safety, etc.).

Suggesting:

Sallam et al. Narra J 2022; 2(1): e74 – doi: 10.52225/narra.v2i1.74

Rosiello et al. Narra J 2021; 1(3): e55-doi: 10.52225/narra.v1i3.55

Methods

1. Calculation of sample size and sample randomization should be disclosed in details.

2. “..careless responses (e.g. censored respondents) and those who withdrew from the survey..” How could censored respondents are categorized as those giving careless responses? Why the participants withdrew from the survey? Didn’t they receive informed consent first?

3. Inclusion and exclusion criteria need to be explicitly disclosed. How authors determine the participants are Korean citizens?

4. Questionnaire validation should be explicitly disclosed. The company identity (name and address) for each statistical software should be stated.

5. What “social organization involvement” means? Is being a member is enough? Should the social organization officially registered? This has to be declared in the methods.

Results

1. Please pay attention on how the data are cited in the text. Usually, the paragraph begins with a sentence indicating where the data are presented. For instance, “Characteristics of the participants have been presented in Table 1”. If authors decide to cite the data in parenthesis, the citation should be made in the first and the last sentence where the data are discussed in the paragraph.

2. For age, consider years old instead of years only.

3. As per international standards, the writing of p<0.000 should be revised to p<0.001

Discussion

1. Authors argue the low willingness in younger generation was resulted from the disinformation spread through social medias, while also arguing that the older generation consumes more reliable information through traditional news sources. Authors cited reference no 6 to strengthen the claim. I don’t think ref 6 is appropriately cited in the manuscript, the literature mainly reports on the preference of news sources for COVID-19 information. Age was only considered as factor affecting the participants’ knowledge on COVID-19, not on their media preference. My suggestion is to modify this part of discussion for better judicious interpretation by readers. Other pronounced factors affecting the disinformation pertaining to COVID-19 (such as education) should be discussed instead.

2. Can you perform the analysis on “social media vs. age” and “social media vs. vaccine trust/hesitancy”?

3. Authors should know that the hesitancy is not always coming from the absence of the knowledge (because of social media as claimed in the manuscript). People who are well informed could also be hesitant because of the safety risk of the vaccine (Rosiello et al. Narra J 2021; 1(3): e55-doi: 10.52225/narra.v1i3.55). Please revise the discussion by considering this.

4. Is there any limitation on the data quality of the SC. For example, being biased or not able to confirm?

Conclusion

1. “COVID-19 experts and celebrities to increase its credibility” Why celebrities are included to increase the credibility?

Reviewer #3: Thank you for the opportunity to review this article. This article has been revised twice. However, I still detected some unclear issues related to this study. Therefore, I include some suggestions that I believe will improve the quality of the manuscript. Please encounter my specific comments in the attached file.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Muhammad Iqhrammullah

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-21-29174_R2_reviewer Review.pdf

PLoS One. 2022 Nov 14;17(11):e0277016. doi: 10.1371/journal.pone.0277016.r006

Author response to Decision Letter 2


13 Oct 2022

Dear Reviewer:

We appreciate your careful review of our manuscript. All authors have read and discussed your comments and revised/corrected the manuscript accordingly.

Please find attached two manuscripts, one is a clean manuscript and the other is a tracked manuscript, which contains all our revisions made using the “Track Changes” feature in Microsoft Word.

We are grateful for your comments that have helped us improve the quality of our manuscript. Thank you in advance for reviewing our responses and revisions.

Sincerely,

Prof. Eun Woo Nam

Attachment

Submitted filename: 03-2.__Reviewer_3__Response_to_Reviewers.docx

Decision Letter 3

Harapan Harapan

17 Oct 2022

PONE-D-21-29174R3Influencing Factor of COVID-19 Vaccination trust and hesitancy in Wonju city, South KoreaPLOS ONE

Dear Dr. Nam,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 01 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Harapan Harapan, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

Please delete the sample size calculation formula since authors did not explain this formula.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Nov 14;17(11):e0277016. doi: 10.1371/journal.pone.0277016.r008

Author response to Decision Letter 3


17 Oct 2022

We deleted the sample size calculation formula in manuscript.

Thank you.

Decision Letter 4

Harapan Harapan

19 Oct 2022

Influencing Factor of COVID-19 Vaccination trust and hesitancy in Wonju city, South Korea

PONE-D-21-29174R4

Dear Dr. Nam,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Harapan Harapan, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Harapan Harapan

25 Oct 2022

PONE-D-21-29174R4

Influencing Factor of COVID-19 Vaccination trust and hesitancy in Wonju city, South Korea

Dear Dr. Nam:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Harapan Harapan

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (PDF)

    S2 File

    (PDF)

    Attachment

    Submitted filename: 3-2. [#Reviewer Comments] response to reviewer.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: PONE-D-21-29174_R2_reviewer Review.pdf

    Attachment

    Submitted filename: 03-2.__Reviewer_3__Response_to_Reviewers.docx

    Data Availability Statement

    Data cannot be shared without permission by Wonju city hall (Healthy City team) publicly, South Korea. Data are available from the Wonju city hall Institutional Data Access (contact via Yeon-seok Jin, jys12076@korea.kr) / Ethics Committee (contact via yuwirb@yonsei.ac.kr/ https://e-irb.yonsei.ac.kr/index.htm?) for researchers who meet the criteria for access to confidential data.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES